title: Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.
abstract: Histone deacetylase inhibitors (HDIs) are a new class of drugs with significant antileukemic activity. To explore mechanisms of disease-specific HDI activity in acute myeloid leukaemia (AML), we have characterised expression of all 18 members of the histone deacetylase family in primary AML blasts and in four control cell types, namely CD34+ progenitors from umbilical cord, either quiescent or cycling (post-culture), cycling CD34+ progenitors from GCSF-stimulated adult donors and peripheral blood mononuclear cells. Only SIRT1 was consistently overexpressed (>2 fold) in AML samples compared with all controls, while HDAC6 was overexpressed relative to adult, but not neo-natal cells. HDAC5 and SIRT4 were consistently underexpressed. AML blasts and cell lines, exposed to HDIs in culture, showed both histone hyperacetylation and, unexpectedly, specific hypermethylation of H3 lysine 4. Such treatment also modulated the pattern of HDAC expression, with strong induction of HDAC11 in all myeloid cells tested and with all inhibitors (valproate, butyrate, TSA, SAHA), and lesser, more selective, induction of HDAC9 and SIRT4. The distinct pattern of HDAC expression in AML and its response to HDIs is of relevance to the development of HDI-based therapeutic strategies and may contribute to observed patterns of clinical response and development of drug resistance.
authors.affiliation: Institute of Biomedical Research, University of Birmingham Medical School, Birmingham B15 2TT, UK.
authors.forename: C A
authors.initials: CA
authors.lastname: Bradbury
authors.forename: F L
authors.initials: FL
authors.lastname: Khanim
authors.forename: R
authors.initials: R
authors.lastname: Hayden
authors.forename: C M
authors.initials: CM
authors.lastname: Bunce
authors.forename: D A
authors.initials: DA
authors.lastname: White
authors.forename: M T
authors.initials: MT
authors.lastname: Drayson
authors.forename: C
authors.initials: C
authors.lastname: Craddock
authors.forename: B M
authors.initials: BM
authors.lastname: Turner
mesh_terms: D000107:Acetylation; D000208:Acute Disease; D000328:Adult; D018952:Antigens, CD34 / Q000378:metabolism; D002087:Butyrates / Q000494:pharmacology; D019175:DNA Methylation; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism*; D006657:Histones / Q000378:metabolism*; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics; D022423:Myeloid Cells; D014407:Tumor Cells, Cultured; D014635:Valproic Acid / Q000494:pharmacology; D000077337:Vorinostat
chemical_list: D018952:Antigens, CD34; D002087:Butyrates; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006657:Histones; D006877:Hydroxamic Acids; C012589:trichostatin A; D000077337:Vorinostat; D014635:Valproic Acid; D006655:Histone Deacetylases